China Human Hepatitis B Vaccine For Long Term Immune Protection Manufacturer, Supplier, Factory

AIM Honesty Biopharmaceutical Co., Ltd., a trusted China-based manufacturer of recombinant vaccines, offers the Human Hepatitis B Vaccine For Long Term Immune Protection—a product developed through the first domestically adopted recombinant Hansenula polymorpha expression technology platform, which originated from a national key technology program. With a production area exceeding 11,000 square meters and an annual capacity of 45 million doses, this vaccine has been used for over 20 years, with cumulative administrations surpassing 480 million doses across China. In 2021, roughly 75% of Chinese newborns received this vaccine. The purification process yields antigen purity up to 99.99%, ensuring strong and durable immune responses. For procurement officers and public health planners, this product offers a proven solution against a virus that chronically infects approximately 296 million people globally and is the leading cause of hepatocellular carcinoma.

The Value of Durable Immunity

For any immunization program, the ultimate measure of success is not just initial seroconversion but the persistence of protection over decades. The Human Hepatitis B Vaccine is engineered to deliver precisely that. Unlike vaccines that require frequent boosters, this product leverages the inherent stability of Hansenula polymorpha‑derived antigens to generate long‑lived plasma cells and memory T cells. Consequently, vaccinated individuals maintain protective antibody levels well beyond the standard decade, and even when titers decline, the immune system rapidly mounts an anamnestic response upon re‑exposure.

Key benefits for long‑term program success:

● Reduced booster frequency: Programs save on logistics and costs because the vaccine’s durability eliminates the need for routine adult boosters.

● Sustained herd immunity: High and lasting protection in vaccinated cohorts contributes to community‑level prevention, reducing transmission even as populations age.

● Proven real‑world longevity: Follow‑up data from vaccinated birth cohorts show that fifteen years after the primary series, chronic infection was completely absent in those who responded to the vaccine – a testament to its enduring efficacy.

How Long‑Term Protection Works

The durability of the Human Hepatitis B Vaccine stems from two complementary immunological pillars: high‑quality initial priming and persistent immune memory. The vaccine uses the Hansenula polymorpha expression platform, which produces HBsAg particles that closely mimic the native viral envelope. This structural fidelity is crucial for eliciting high‑affinity neutralising antibodies and robust CD4+ and CD8+ T‑cell responses.

● Strong primary response: More than 98% of healthy vaccinees achieve anti‑HBs ≥10 mIU/mL after the standard three‑dose schedule. This high seroconversion rate ensures that nearly all recipients start with a solid immunological foundation.

● Memory B‑cell persistence: The vaccine induces long‑lived memory B cells that reside in bone marrow and lymphoid tissues. These cells can be rapidly reactivated to produce neutralising antibodies upon exposure, even after antibody titres have waned.

● Cellular immunity reservoir: The Hansenula polymorpha platform is uniquely effective at stimulating cytotoxic T lymphocytes (CTLs) and IFN‑γ‑producing cells. This cellular arm of immunity is critical for eliminating infected hepatocytes and preventing chronic carriage, and it persists for many years after vaccination.

Platform Advantages for Sustained Response

Not all hepatitis B vaccines offer the same longevity. The Human Hepatitis B Vaccine is built on the advanced Hansenula polymorpha yeast system, which outperforms both first‑generation yeast and mammalian cell platforms in several ways that directly impact durability.

The table clearly shows that the Hansenula polymorpha platform delivers the highest purity and strongest cellular immunity – both essential for lasting protection. The absence of animal‑derived additives and antibiotics also reduces allergy risks, making the vaccine suitable for lifelong use in diverse populations.

Clinical Experience Across Decades

Real‑world evidence confirms that the Human Hepatitis B Vaccine provides enduring defence. In a large‑scale evaluation involving children aged 5‑15 years who received a booster with the 10 µg RECVAX® (Hansenula polymorpha) vaccine, the anti‑HBs seropositivity rates at 1, 5, and 8 years post‑booster reached 83.4% – the highest among all comparator vaccines. More importantly, long‑term surveillance of cohorts vaccinated from infancy shows that fifteen years after primary immunisation, only a small fraction had evidence of past infection, and critically, none had progressed to chronic hepatitis B. This absence of chronic infection is the ultimate proof of durable protection, as chronic carriage is the primary driver of liver cirrhosis and cancer.

● The vaccine’s ability to prevent chronic infection, not just acute disease, is what makes it a cornerstone of national hepatitis B control strategies.

● The 10 µg dose, effective for all ages, achieves these outcomes without the need for higher doses or more frequent boosters, simplifying program logistics.

Who Benefits Most from Long‑Term Protection

The Human Hepatitis B Vaccine For Long Term Immune Protection is designed for all susceptible individuals, but certain groups derive exceptional value from its durability.

Newborns of carrier mothers: Immediate vaccination within 24 hours of birth, combined with HBIG, reduces transmission by over 95%. The lasting immunity ensures that these high‑risk children remain protected through adolescence and adulthood, when exposure risks may increase.

Healthcare workers: Occupational exposure to blood is a continuous hazard. The vaccine’s long‑lasting protection eliminates the need for frequent serological monitoring and boosters, saving time and resources for hospitals and clinics.

Patients with chronic conditions: Individuals on haemodialysis, those with liver disease, or immunocompromised patients often respond poorly to standard vaccines. The enhanced immunogenicity of the Hansenula polymorpha platform gives them a better chance at durable protection.

Travelers and expatriates: For people moving to or visiting endemic regions, a single complete series provides protection that lasts for decades, removing the hassle of pre‑trip booster shots.

Manufacturing Consistency for Reliable Outcomes

Consistent production quality is the bedrock of predictable long‑term protection. The Human Hepatitis B Vaccine is manufactured by AIM Honesty Biopharmaceutical Co., Ltd., established in 1993 as one of China’s pioneering vaccine enterprises. With a registered capital of RMB 250 million and a national postdoctoral workstation, the company maintains GMP‑certified facilities covering over 11,000 square metres. The production process includes fermentation, purification, formulation, and filling – each step tightly controlled to ensure batch‑to‑batch consistency. Antigen purity routinely exceeds 99.99%, and each lot undergoes rigorous testing for potency, sterility, endotoxin, and residual impurities. This uncompromising quality assurance guarantees that every dose delivers the same high level of immunogenicity, supporting reliable long‑term outcomes for every recipient.

● The vaccine received National Drug Approvals (10 µg in 2004, 20 µg in 2013) and GMP certification in 2004, with regular regulatory inspections ever since.

● Over 480 million doses have been distributed without any vaccine‑related safety signals, underscoring the manufacturing excellence.

Global Access and Supply Stability

Durable protection is only meaningful if the vaccine is reliably available. AIM Vaccine Co., Ltd. (06660.HK) – the parent company – is the world’s largest producer of hepatitis B vaccines. The Human Hepatitis B Vaccine is exported to South America, Central Asia, South Asia, and Africa, with government partnerships in Pakistan, Kenya, and Egypt. Annual capacity of 45 million doses ensures that both routine programmes and emergency procurement can be fulfilled without delays. Cold‑chain logistics are meticulously managed at 2‑8°C, and the company provides comprehensive support for import documentation and regulatory compliance. Delivery is typically completed within 30 working days after order confirmation, offering procurement officers a dependable supply chain for sustained public health impact.

Frequently Asked Questions

Q: How long does the vaccine’s protection actually last?

A: Clinical follow‑up of vaccinated birth cohorts shows that protective immunity persists for at least 15 years, with no chronic infections occurring in responders. Even when antibody levels decline, immunological memory ensures a rapid response upon exposure.

Q: Is a booster dose necessary for adults?

A: For healthy individuals who completed a full primary series, routine boosters are not recommended. The vaccine’s durable immune memory provides ongoing protection. Booster doses may be considered for immunocompromised patients or those with ongoing high‑risk exposure, as determined by healthcare providers.

Q: Can the 10 µg dose be used for adults, or is a higher dose needed?

A: The 10 µg formulation is fully effective for all age groups, including adults, due to the superior immunogenicity of the Hansenula polymorpha platform. This eliminates the need for separate adult formulations, simplifying inventory management.

Q: What is the storage requirement for maintaining long‑term product stability?

A: The vaccine must be stored at 2‑8°C, protected from light, and never frozen. Under these conditions, the shelf life is 36 months. Cold‑chain integrity during transport is essential to preserve immunogenicity.

Q: Does the vaccine contain thiomersal or other preservatives?

A: No. The vaccine is preservative‑free and contains no thiomersal, antibiotics, or bovine serum albumin, minimising the risk of allergic reactions and enhancing safety for all recipients.

Q: How does this vaccine compare to other hepatitis B vaccines in terms of cost‑effectiveness?

A: Its long‑lasting protection reduces the need for boosters and associated healthcare visits, lowering overall program costs. The high purity and strong immunogenicity also mean fewer non‑responders, reducing wastage and improving program efficiency.

Q: Has the manufacturing facility been inspected by international regulators?

A: While the company is actively pursuing PIC/S member country inspections, it already maintains strict GMP compliance with Chinese NMPA standards, which are aligned with WHO recommendations.

Partner for Sustainable Hepatitis Prevention

Choosing the Human Hepatitis B Vaccine For Long Term Immune Protection means investing in a vaccine that delivers not just immediate seroconversion but decades‑long defence against a disease that claims hundreds of thousands of lives annually. AIM Honesty Biopharmaceutical Co., Ltd. brings over 30 years of vaccine manufacturing expertise, a robust quality system, and a proven export track record. Procurement agencies receive full support: regulatory dossiers, cold‑chain logistics coordination, flexible packaging, and responsive after‑sales service. By partnering with AIM Honesty, you secure a reliable supply of a vaccine that has already protected hundreds of millions, and you contribute to the global goal of hepatitis B elimination. Contact the international sales team today for technical details, sample requests, or to discuss customised supply solutions.